• Most Popular
  • Most Shared

FEATURE-Profit drives drug misuse in Asia

Sun Apr 5, 2009 8:04pm EDT

Stocks

   
By Fitri Wulandari and Tan Ee Lyn

JAKARTA/HONG KONG, April 6 (Reuters) - Ria Pane took her 7-year-old daughter Kezia to a doctor in Jakarta to check on her fever and sore throat, and was prescribed seven drugs, including antibiotics and medicine to prevent febrile seizures.

Experts say it was another classic, but only too common, case of over-medication, or prescribing drugs patients do not need. Here, the antibiotic was unnecessary, as was the drug to prevent febrile seizures as the child had no history of such attacks, said several pharmacists and doctors who were asked by Reuters.

Experts warn that driven by profits from selling medicine, some doctors from Indonesia to Hong Kong are overprescribing medicines, a practise they say will be disastrous in the longer term.

"Polypharmacy (overmedication) is very popular here, it means they use a lot of medicines which are unnecessary, like giving you many types of antibiotics for a cold," said William Chui, honorary associate professor at the Clinical Trials Centre attached to the University of Hong Kong.

"Every time they sell a drug, they get a profit, it is a profit motive. When they give lots of medicine, parents feel happier, more happy than when they are told to go home to sleep."

The consumption of multiple drugs triggers drug reaction and unpredictable side effects. Worse, it gives rise to bacterial resistance.

The most recent example of growing resistance involves the drug oseltamivir, which researchers in the United States found was now ineffective against 98 percent of the H1N1 seasonal human influenza virus strains.

Oseltamivir is known by the brand Tamiflu and manufactured by Roche AG (ROG.VX).

Oseltamivir is also recommended as a first line of defence against the H5N1 bird flu virus in case it triggers a flu pandemic and experts are now questioning how well, and how long, the drug will stand up against the H5N1 virus.

SERIOUS SIDE EFFECTS

Apart from eventually reducing the effectiveness of drugs, exposing bacteria and viruses to drugs unnecessarily also has other serious consequences.

"They harm the patient. The more drugs, the worse the compliance, especially for old people. They fall easily because of drug interaction and side effects. They get dizzy, hypotension, it is something we don't recommend," Chui said.

Doctors in Indonesia often prescribe antibiotics to patients suffering a common cold when such drugs are only to be used for bacterial infections.

"Most parents rush to treat symptoms, not the disease. Doctors may feel pressure to give treatments, even when it is not necessary or in the best interests of the child's health," said Purnamawati S. Pujiarto, a paediatrician trying to promote a more informed use of drugs in Indonesia.

Experts say such a mentality has led not only to polypharmacy, but also the use of compounding medicine, known in Indonesia as "puyer".

Compounding medicine is the practise of crushing different drugs into a powder in a bowl and dividing it into small sachets. Sometimes it is mixed with syrups.

It is carried out under strict guidelines in some countries. But in Indonesia, it has been used liberally for decades, particularly to treat health problems in children.

Experts warn this practise could result in errors as the drugs may not be evenly divided or pharmacists may not clean the bowl thoroughly, leaving residues from previous prescriptions.

"The issue is not 'puyer' itself but the competence and knowledge," said Iwan Dwiprahasto, a pharmacoepidemiology professor at Gadjah Mada University in Yogyakarta.

"Does the pharmacist know which drugs are not allowed to be compounded? Do doctors know certain drugs are not allowed to be mixed together because they are dangerous to patients?"

"The compounded form makes patients unaware they have consumed many drugs as it looks like a single medicine," said Dwiprahasto, who is also chairman of the Indonesian Pharmacologist Association.

RESISTANCE

In Hong Kong, Chui and his colleagues recently discovered widespread abuse of carbapenem, a class of the powerful, broad-spectrum antibiotic in private hospitals.

This class of antibiotics is recommended as a prophylaxis for major procedures such as colorectal operations, but pharmacists found they were given to patients even for minor procedures.

"Alternative prophylaxis require three doses a day, but this is just one dose daily. Private hospitals use this as it's very convenient and it's broad spectrum so it can block all infections," said Chui.

"But what we are most afraid of is resistance especially with the (bacteria) stenotrophomonas maltophilia. If you abuse carbapenem, this bacteria will get more resistant."

Stenotrophomonas maltophilia is a bacteria that causes uncommon infections that are difficult to treat, such as pneumonia, urinary tract infection or blood stream infection. (Editing by Sugita Katyal)





Indonesia



More from Reuters

A Greenpeace activist dressed as one of the "Four Horsemen of the Apocalypse" rides outside the parliament building during a brief protest in Copenhagen December 13, 2009.   REUTERS/Christian Charisius

The face of climate protest

Protesters around the globe called for an end to global warming as climate talks in Copenhagen entered their sixth day.  Video 

    President Barack Obama (R) meets with financial services industry leaders in the Roosevelt Room of the White House in Washington December 14, 2009. REUTERS/Larry Downing

    Obama takes "fat cats" to task

    Backed by Americans outraged by multi-billion dollar bailouts, President Obama met with a dozen of Wall Street's top bankers in a bid to crack down on the so-called "fat cats" largely held responsible for the financial crisis.  Full Article 

    Lockheed Martin Chief Executive Robert Stevens answers a question during the Reuters Aerospace and Defense Summit in Washington December 14, 2009.  REUTERS/Molly Riley

    Lockheed eyes deals

    The future demands of cybersecurity make that sector one of many the aerospace giant sees as an acquisition target in the coming year.  Full Article